Denis Logunov - Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine - an interim analysis of a randomised controlled phase 3 trial in Russia

Declaration of interests

OVZ, TAO, IVD, OP, DVS, DMG, ASD, AIT, DNS, IBE, EAT, AGB,

ASE, ASS, SVB, DYL, BSN, and ALG report patents for an immunobiological expression vector, pharmaceutical agent, and its method of use to prevent COVID-19. All other authors declare no competing interests.

Data sharing

Anonymous participant data will be available upon completion of clinical trials and publication of the results of the completed study upon request to the corresponding author. Proposals will be reviewed and approved by the sponsor, security department, researcher, and staff on the basis of scientific merit and absence of competing interests. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

Acknowledgments

We would like to thank the study participants, site research staff, and members of the trial management groups, trial steering committee, and IDMC.

References

1 WHO. Draft landscape of COVID-19 candidate vaccines.

Jan 22, 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines(accessed Jan 23, 2021).

2 Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99-111.

3 Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; published online Dec 30. https://doi.org/10.1056/NEJMoa2035389.

4 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15.

5 Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother 2016;

12: 2064—74.

6 Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 2013;

13:421-33.

7 Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6 (suppl 1): S164—71.

8 Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-29.

9 Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother 2017; 13: 613-20.

10 Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21: 346-51.

11 Kovyrshina AV, Dolzhikova IV, Grousova DM, et al. A heterologous virus-vectored vaccine for prevention of Middle East respiratory syndrome induces long protective immune response against MERS-CoV. Immunologiya 2020; 41: 135-43 (in Russian).

12 Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020;

396: 887-97

13 Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.

14 WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. July 9, 2020. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions(accessed Dec 1, 2020).

15 Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Updated Dec 8, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (accessed Dec 29, 2020).

16 WHO. Target product profiles for COVID-19 vaccines.

April 9, 2020. https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines(accessed Dec 1, 2020).